DAX21.732 ±0,0%ESt505.287 +0,1%Top 10 Crypto16,30 -3,2%Dow44.545 -0,8%Nas19.627 -0,3%Bitcoin97.708 -1,1%Euro1,0369 -0,2%Öl76,77 -0,4%Gold2.801 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T Siemens Energy ENER6Y Rheinmetall 703000 Apple 865985 Microsoft 870747 Amazon 906866 Commerzbank CBK100 Palantir A2QA4J Deutsche Telekom 555750 Infineon 623100 Deutsche Bank 514000 BASF BASF11 Bayer BAY001 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen mit Minus ins Wochenende -- DAX schließt marginal höher -- Apple überzeugt beim Gewinn -- Goldpreis auf Rekordhoch -- Intel , Atlassian, Samsung, Visa, HPE und Juniper im Fokus
Top News
Performance der Kryptowährungen Bitcoin, Dogecoin, Ethereum & Co. am Samstagnachmittag Performance der Kryptowährungen Bitcoin, Dogecoin, Ethereum & Co. am Samstagnachmittag
ZEEKR mit Auslieferungszahlen für Januar - Wichtiger Meilenstein rückt näher ZEEKR mit Auslieferungszahlen für Januar - Wichtiger Meilenstein rückt näher
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Welche Kreditkarte passt zu Ihnen? Hier geht es zum Vergleich!

Novavax Aktie

NeuKaufenVerkaufen
Novavax Aktien-Sparplan
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.1,34 Mrd. EUR

Div. Rendite0,00%

WKNA2PKMZ

ISINUS6700024010

SymbolNVAX

Novavax Aktien News

DatumMeistgelesen
PR NewswireNovavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
PR NewswireNovavax gibt eine Vereinbarung mit dem Bill & Melinda Gates Medical Research Institute über die Aufnahme des Matrix-M™ Adjuvanten als potenzielle Komponente in der Impfstoffforschung bekannt
PR NewswireNovavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
PR NewswireNovavax to Participate in the Jefferies Global Healthcare Conference
PR NewswireNuvaxovid™ von Novavax erhält positive CHMP-Stellungnahme für vollständige Marktzulassung zur Prävention von COVID in der EU
PR NewswireNovavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU
PR NewswireNovavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU
PR NewswireAccess to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
PR NewswireAccess to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
PR NewswireNovavax Reports First Quarter 2023 Financial Results and Operational Highlights
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswirePositive Phase-2-Topline-Ergebnisse zeigen, dass die COVID-Influenza-Kombination, eigenständige Influenza- und hochdosierte COVID-Impfstoffkandidaten von Novavax robuste Immunreaktionen auslösen
PR NewswirePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
PR NewswireNovavax to Participate in the BofA Securities 2023 Health Care Conference
PR NewswireNovavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023
PR NewswireNovavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
PR NewswireNovavax to Participate in TD Cowen's 43rd Annual Health Care Conference
PR NewswireNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
PR NewswireNovavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
PR NewswireNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireVerlängerung der Partnerschaft zwischen der US-Regierung und Novavax zur Bereitstellung von bis zu 1,5 Millionen zusätzlichen Dosen des COVID-19-Impfstoffs von Novavax
PR NewswireU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
PR NewswireNovavax Names John C. Jacobs as New President & Chief Executive Officer
PR NewswireNovavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
PR NewswireNovavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
PR NewswireNovavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference
PR NewswireWeltgesundheitsorganisation aktualisiert die Notfallliste für COVID-19-Impfstoff Nuvaxovid von Novavax als Primärserie bei Jugendlichen und als Booster bei Erwachsenen
PR NewswireWorld Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
PR NewswireWorld Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
PR NewswireNovavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults
PR NewswireNovavax to Participate in Jefferies London Healthcare Conference
PR NewswireNovavax Phase-3-Studie COVID-19 Omikron unterstützt den weiteren und zukünftigen Einsatz des Novavax Prototyp-Impfstoffs als Booster
Wer­bung

Novavax News

Novavax News: auf dieser Seite finden Sie alle Novavax News und Nachrichten zur Novavax Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novavax News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novavax News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.